

**North America Immunodiagnosics Market Forecast to 2030 - Regional Analysis - by Product (Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others), By Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)**

Market Report | 2023-10-27 | 200 pages | The Insight Partners

**AVAILABLE LICENSES:**

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

**Report description:**

The North America immunodiagnosics market is expected to grow from US\$ 10,463.48 million in 2023 to US\$ 17,399.10 million by 2030. It is estimated to grow at a CAGR of 7.5% from 2023 to 2030.

Growing Use of Point-of-Care Immunodiagnosics Drive North America Industrial Robotics Market

Point-of-care testing (POCT) has become critical to patient-centric healthcare due to the need for rapid diagnostic results to determine accurate and faster treatments. A shift from centralized point-of-care testing to decentralized testing has resulted in easy access to these diagnostics. Immunoassay testing helps monitor chronic conditions and detect pathogens, such as bacteria and viruses. Advanced point-of-care devices enable rapid screening of up to three components from a single sample. Also, the point-of-care diagnostics (POCD) inclined toward mobile healthcare (mH) smart devices could revolutionize personalized healthcare monitoring and management, paving the way for next-generation POCTs. The management of infectious diseases can be significantly improved by POCTs, particularly in developing countries where access to timely medical care is challenging and healthcare infrastructure is outdated and sparse. Additionally, the technologically developed diagnostic kits leading to fewer

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scott's-international.com](mailto:support@scott's-international.com)

[www.scott's-international.com](http://www.scott's-international.com)

manual errors propel the immunodiagnosics market. Several market players are developing innovative immunodiagnosics products. For instance, Thermo Fisher Scientific has developed immunodiagnosics products such as enzyme-linked immunoassay (ELISA) reagents and buffers, antibodies and detection probes, linking mechanisms, blocking buffers and detergents, detection substrates, and capture surfaces, as well as services such as bioconjugation and detection. Further, in September 2020, Roche launched the SARS-CoV-2 Rapid Antigen Test, which is used in POC settings to help healthcare professionals identify the infection within 15 minutes in people suspected of carrying the virus.

In April 2021, DiaSorin introduced the LIAISON IQ, a new immunodiagnosics Point-of-Care (POC) reader, and the LIAISON QuickDetect COVID TrimericS Ab test, developed with Lumos Diagnostics for countries accepting the CE Mark. Using a fingerstick of human capillary blood, this test for the LIAISON IQ identifies specific IgG antibodies against SARS-CoV-2 Spike Protein in 10 minutes.

In April 2021, Chembio Diagnostics, Inc. launched an FDA Emergency Use Authorization-approved, in-licensed rapid point-of-care COVID-19/Flu A&B test for use in traditional and decentralized testing settings. The rapid immunoassay test requires no instrumentation and produces results in 15 minutes.

WHO applauded the test kit developers for efforts taken to innovate and respond to the masses' requirements during the COVID-19 crisis. According to the American Society for Clinical Pathology, in March 2020, the Cepheid Xpert Xpress SARS-CoV-2 test became the first POC COVID-19 detection assay to receive Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA).

Likewise, the use of immunodiagnosics in cancer treatment is increasing. In oncology, an immunodiagnosics test can confirm the presence of a solid tumor by detecting known tumor-associated antigens or antibodies. These advantages and indications are driving the immunodiagnosics market.

#### North America Immunodiagnosics Market Overview

The prevalence of cancer is increasing in the country at an alarming rate, leading to the rising demand for cancer diagnoses. According to the American Cancer Society's (ACS) cancer facts & figures estimates for 2023, nearly 1.9 million new cancer cases were registered in the US. It is further projected that in 2023, the country will register 609,360 deaths from cancer, which is ~1,670 deaths a day. However, the increased diagnostics have reduced the number of cancer-linked deaths. As per the ACS, in the past 28 years, the death rate from cancer in men and women has fallen 32% from its peak in 1991 to 2019. The fall in death rates was found to be because of early and advanced cancer diagnoses. The awareness of the advancements in diagnostic technology has grown among people. Therefore, it has resulted in the significant growth of the immunoassay market in the US. Similarly, diabetes is prevailing at a high rate in the geriatric population in the US. Many companies are providing immunoassay kits for diabetes. For instance, Bio-Rad Laboratories, Inc. offers Bio-Plex Pro human diabetes immunoassays, which are reliable and convenient for studying human diabetes and obesity markers. They help in managing and treating diabetes in diabetic patients. The market is expected to witness significant growth due to the rising prevalence of diabetes among US citizens. According to the data published by the Centers for Disease Control and Prevention (CDC) in the 2023 National Diabetes Statistics Report, 37.3 million people have diabetes in the US, which accounts for 11.3% of the total US population. Also, the reports state that 96 million people aged 18 years or above are prediabetic, accounting for 38% of the US population. Thus, considering the prevalence of diabetes in the country, an increased demand for immunodiagnosics is anticipated, leading to market growth. There has been unprecedented growth in innovative and improved medical technologies in recent years. As a result, there have been developments in advanced diagnostics and the overall healthcare industry. Moreover, the US houses various companies developing cutting-edge products for point-of-care diagnosis, paving the way for the growth of the immunodiagnosics market. In April 2020, Bio-Rad Laboratories launched a blood-based immunoassay kit to identify antibodies to the SARS-CoV-2.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## North America Immunodiagnosics Market Segmentation

The North America immunodiagnosics market is segmented into product, clinical indication, end user, and country.

Based on product, the North America immunodiagnosics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. In 2023, the enzyme-linked immunosorbent assays (ELISA) segment registered the largest share in the North America immunodiagnosics market. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.

Based on clinical indication, the North America immunodiagnosics market is segmented into infectious diseases, hepatitis+HIV, endocrinology, gastrointestinal, metabolics, and others. In 2023, the infectious diseases segment registered the largest share in the North America immunodiagnosics market. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.

Based on end user, the North America immunodiagnosics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. In 2023, the hospitals segment registered the largest share in the North America immunodiagnosics market.

Based on country, the North America immunodiagnosics market is segmented into the US, Canada, Mexico. In 2023, the US registered the largest share in the North America immunodiagnosics market.

Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc are some of the leading companies operating in the North America immunodiagnosics market.

## Table of Contents:

### TABLE OF CONTENTS

1. Introduction
  - 1.1 Scope of the Study
  - 1.2 The Insight Partners Research Report Guidance
  - 1.3 Market Segmentation
    - 1.3.1 North America Immunodiagnosics Market - by Product
    - 1.3.2 North America Immunodiagnosics Market - by Clinical Indication
    - 1.3.3 North America Immunodiagnosics Market - by End User
    - 1.3.4 North America Immunodiagnosics Market - by Country
2. North America Immunodiagnosics Market - Key Takeaways
3. Research Methodology
  - 3.1 Coverage
  - 3.2 Secondary Research
  - 3.3 Primary Research
4. North America Immunodiagnosics Market - Market Landscape
  - 4.1 Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 4.2 North America PEST Analysis
- 4.3 Expert's Opinion
- 5. North America Immunodiagnosics Market - Key Market Dynamics
  - 5.1 Market Drivers
    - 5.1.1 Increasing Prevalence of Infectious Diseases
    - 5.1.2 Growing Use of Point-of-Care Immunodiagnosics
  - 5.2 Market Restraints
    - 5.2.1 Inadequate Reimbursement Scenario
  - 5.3 Market Opportunities
    - 5.3.1 Rising Focus on R&D Investment and Expansion by Key Players
  - 5.4 Future Trends
    - 5.4.1 Technological Advancements in Immunodiagnosics
  - 5.5 Impact Analysis
- 6. Immunodiagnosics Market - North America Analysis
  - 6.1 North America Immunodiagnosics Market Revenue Forecast and Analysis
- 7. North America Immunodiagnosics Market Analysis - by Product
  - 7.1 Overview
  - 7.2 North America Immunodiagnosics Market, By Product, 2022 & 2030 (%)
  - 7.3 Enzyme-linked Immunosorbent Assays (ELISA)
    - 7.3.1 Overview
    - 7.3.2 Enzyme-linked Immunosorbent Assays (ELISA): North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
  - 7.4 Chemiluminescence Immunoassays (CLIA)
    - 7.4.1 Overview
    - 7.4.2 Chemiluminescence Immunoassays (CLIA): North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
    - 7.4.3 Vitamin D Assay
      - 7.4.3.1 Overview
      - 7.4.3.2 Vitamin D Assay: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
    - 7.4.4 HIV Detection
      - 7.4.4.1 Overview
      - 7.4.4.2 HIV Detection: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
    - 7.4.5 HIV Ag/Ab Combo assay
      - 7.4.5.1 Overview
      - 7.4.5.2 HIV Ag/Ab Combo Assay: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
    - 7.4.6 Other Tests
      - 7.4.6.1 Overview
      - 7.4.6.2 Other Tests: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
  - 7.5 Radioimmunoassays (RIA)
    - 7.5.1 Overview
    - 7.5.2 Radioimmunoassays (RIA): North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
  - 7.6 Others
    - 7.6.1 Overview
    - 7.6.2 Others: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8. North America Immunodiagnosics Market Analysis - Clinical Indication
  - 8.1 Overview
  - 8.2 North America Immunodiagnosics Market Share by Clinical Indication - 2022 & 2030 (%)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

### 8.3 Infectious Diseases:

#### 8.3.1 Overview

#### 8.3.2 Infectious Diseases: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)

##### 8.3.2.1 COVID-19

###### 8.3.2.1.1 Overview

###### 8.3.2.1.2 COVID-19: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)

##### 8.3.2.2 Tuberculosis

###### 8.3.2.2.1 Overview

###### 8.3.2.2.2 Tuberculosis: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)

##### 8.3.2.3 Lyme

###### 8.3.2.3.1 Overview

###### 8.3.2.3.2 Lyme: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)

##### 8.3.2.4 Infection Management

###### 8.3.2.4.1 Overview

###### 8.3.2.4.2 Infection Management: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)

##### 8.3.2.5 Zika

###### 8.3.2.5.1 Overview

###### 8.3.2.5.2 Zika: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)

##### 8.3.2.6 Treponema

###### 8.3.2.6.1 Overview

###### 8.3.2.6.2 Treponema: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)

##### 8.3.2.7 TORCH

###### 8.3.2.7.1 Overview

###### 8.3.2.7.2 TORCH: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)

##### 8.3.2.8 Measles and Mumps

###### 8.3.2.8.1 Overview

###### 8.3.2.8.2 Measles and Mumps: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)

##### 8.3.2.9 VZV

###### 8.3.2.9.1 Overview

###### 8.3.2.9.2 VZV: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)

##### 8.3.2.10 EBV

###### 8.3.2.10.1 Overview

###### 8.3.2.10.2 EBV: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)

### 8.4 Hepatitis+HIV:

#### 8.4.1 Overview

#### 8.4.2 Hepatitis+HIV: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)

### 8.5 Gastrointestinal

#### 8.5.1 Overview

#### 8.5.2 Gastrointestinal: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)

### 8.6 Metabolic Disorders

#### 8.6.1 Overview

#### 8.6.2 Metabolics: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)

### 8.7 Endocrinology

#### 8.7.1 Overview

#### 8.7.2 Endocrinology: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)

#### 8.7.3 Hypertension

##### 8.7.3.1 Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.7.3.2 Hypertension: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.7.4 Growth
  - 8.7.4.1 Overview
  - 8.7.4.2 Growth: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.7.5 Diabetes
  - 8.7.5.1 Overview
  - 8.7.5.2 Diabetes: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.7.6 Thyroid
  - 8.7.6.1 Overview
  - 8.7.6.2 Thyroid: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.7.7 Reproductive Endocrinology
  - 8.7.7.1 Overview
  - 8.7.7.2 Reproductive Endocrinology: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.8 Others
  - 8.8.1 Overview
  - 8.8.2 Others: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 9. North America Immunodiagnosics Market Analysis - End User
  - 9.1 Overview
  - 9.2 North America Immunodiagnosics Market Share by End User - 2022 & 2030 (%)
  - 9.3 Hospitals
    - 9.3.1 Overview
    - 9.3.2 Hospitals: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
  - 9.4 Clinics
    - 9.4.1 Overview
    - 9.4.2 Clinics: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
  - 9.5 Diagnostic Laboratories
    - 9.5.1 Overview
    - 9.5.2 Diagnostic Laboratories: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
  - 9.6 Academic and Research Institutes
    - 9.6.1 Overview
    - 9.6.2 Academic and Research Institutes: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
  - 9.7 Others
    - 9.7.1 Overview
    - 9.7.2 Others: North America Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 10. North America Immunodiagnosics Market - Revenue and Forecast to 2030 - Country Analysis
  - 10.1 Overview
    - 10.1.1.1 US: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
      - 10.1.1.1.1 Overview
      - 10.1.1.1.2 US: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
      - 10.1.1.1.3 US: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
        - 10.1.1.1.3.1 US: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
        - 10.1.1.1.4 US: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
          - 10.1.1.1.4.1 US: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
          - 10.1.1.1.4.2 US: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
        - 10.1.1.1.5 US: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
      - 10.1.1.2 Canada: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.1.1.2.1 Overview
- 10.1.1.2.2 Canada: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
- 10.1.1.2.3 Canada: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
  - 10.1.1.2.3.1 Canada: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
  - 10.1.1.2.4 Canada: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
    - 10.1.1.2.4.1 Canada: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
    - 10.1.1.2.4.2 Canada: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
  - 10.1.1.2.5 Canada: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
- 10.1.1.3 Mexico: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
  - 10.1.1.3.1 Overview
  - 10.1.1.3.2 Mexico: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
  - 10.1.1.3.3 Mexico: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
    - 10.1.1.3.3.1 Mexico: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
    - 10.1.1.3.4 Mexico: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
      - 10.1.1.3.4.1 Mexico: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
      - 10.1.1.3.4.2 Mexico: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
    - 10.1.1.3.5 Mexico: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
- 11. North America Immunodiagnosics Market -Industry Landscape
  - 11.1 Overview
  - 11.2 Inorganic Growth Strategies
    - 11.2.1 Overview
  - 11.3 Organic Growth Strategies
    - 11.3.1 Overview
- 12. Company Profiles
  - 12.1 Abbott Laboratories
    - 12.1.1 Key Facts
    - 12.1.2 Business Description
    - 12.1.3 Products and Services
    - 12.1.4 Financial Overview
    - 12.1.5 SWOT Analysis
    - 12.1.6 Key Developments
  - 12.2 F. Hoffmann-La Roche Ltd
    - 12.2.1 Key Facts
    - 12.2.2 Business Description
    - 12.2.3 Products and Services
    - 12.2.4 Financial Overview
    - 12.2.5 SWOT Analysis
    - 12.2.6 Key Developments
  - 12.3 DiaSorin SpA
    - 12.3.1 Key Facts
    - 12.3.2 Business Description
    - 12.3.3 Products and Services
    - 12.3.4 Financial Overview
    - 12.3.5 SWOT Analysis
    - 12.3.6 Key Developments

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.4 Danaher Corp
  - 12.4.1 Key Facts
  - 12.4.2 Business Description
  - 12.4.3 Products and Services
  - 12.4.4 Financial Overview
  - 12.4.5 SWOT Analysis
  - 12.4.6 Key Developments
- 12.5 Thermo Fisher Scientific Inc
  - 12.5.1 Key Facts
  - 12.5.2 Business Description
  - 12.5.3 Products and Services
  - 12.5.4 Financial Overview
  - 12.5.5 SWOT Analysis
  - 12.5.6 Key Developments
- 12.6 PerkinElmer Inc
  - 12.6.1 Key Facts
  - 12.6.2 Business Description
  - 12.6.3 Products and Services
  - 12.6.4 Financial Overview
  - 12.6.5 SWOT Analysis
  - 12.6.6 Key Developments
- 12.7 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  - 12.7.1 Key Facts
  - 12.7.2 Business Description
  - 12.7.3 Products and Services
  - 12.7.4 Financial Overview
  - 12.7.5 SWOT Analysis
  - 12.7.6 Key Developments
- 12.8 bioMerieux SA
  - 12.8.1 Key Facts
  - 12.8.2 Business Description
  - 12.8.3 Products and Services
  - 12.8.4 Financial Overview
  - 12.8.5 SWOT Analysis
  - 12.8.6 Key Developments
- 12.9 Svar Life Science AB
  - 12.9.1 Key Facts
  - 12.9.2 Business Description
  - 12.9.3 Products and Services
  - 12.9.4 Financial Overview
  - 12.9.5 SWOT Analysis
  - 12.9.6 Key Developments
- 12.10 Siemens Healthcare GmbH
  - 12.10.1 Key Facts
  - 12.10.2 Business Description
  - 12.10.3 Products and Services
  - 12.10.4 Financial Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
- 13. Appendix
  - 13.1 About The Insight Partners
  - 13.2 Glossary of Terms

**North America Immunodiagnosics Market Forecast to 2030 - Regional Analysis - by Product (Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others), By Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)**

Market Report | 2023-10-27 | 200 pages | The Insight Partners

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User Price	\$3000.00
	Site Price	\$4000.00
	Enterprise Price	\$5000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-04"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com